Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RBOT Stock Forecast 2026-2027
$0.55
Current Price
$3.92M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RBOT Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
RBOT Price Momentum
+17.0%
1 Week Change
-26.7%
1 Month Change
-93.6%
1 Year Change
-74.7%
Year-to-Date Change
-96.0%
From 52W High of $13.75
+103.7%
From 52W Low of $0.27
📊 TOP ANALYST CALLS
Did RBOT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if D8 Holdings is one of their latest high-conviction picks.
Latest RBOT Stock Price Targets & Analyst Predictions
RBOT has shown a year-to-date change of -74.7% and a 1-year change of -93.6%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for RBOT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RBOT Analyst Ratings
0
Buy
1
Hold
0
Sell
RBOT Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.55
Latest RBOT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RBOT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 13, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $7.00 |
| Mar 18, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $8.50 |
| Nov 13, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $10.50 |
| Aug 13, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $12.00 |
| Jul 15, 2024 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $10.00 |
| Mar 5, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $1.00 |
| Dec 4, 2023 | Morgan Stanley | Patrick Wood | Equal-Weight | Initiates | $0.60 |
| Nov 14, 2023 | Canaccord Genuity | Caitlin Cronin | Hold | Downgrade | $0.40 |
| Nov 14, 2023 | BTIG | Ryan Zimmerman | Neutral | Downgrade | $N/A |
| May 31, 2023 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $9.00 |
| Jul 18, 2022 | BTIG | Ryan Zimmerman | Buy | Maintains | $7.00 |
| May 10, 2022 | Piper Sandler | Adam Maeder | Neutral | Maintains | $5.00 |
| Mar 4, 2022 | Piper Sandler | Adam Maeder | Neutral | Downgrade | $7.00 |
| Mar 4, 2022 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 7, 2022 | Credit Suisse | Outperform | Initiates | $N/A | |
| Dec 7, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Nov 5, 2021 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Oct 18, 2021 | BTIG | Buy | Initiates | $N/A | |
| Oct 7, 2021 | Piper Sandler | Overweight | Initiates | $N/A |
Vicarious Surgical Inc. (RBOT) Competitors
The following stocks are similar to D8 Holdings based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RBOT
D8 Holdings
mkt cap
3.47M
Vicarious Surgical Inc. (RBOT) Financial Data
Vicarious Surgical Inc. has a market capitalization of $3.92M with a P/E ratio of 49.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -509.9%.
Valuation Metrics
Market Cap
$3.92M
Enterprise Value
$9.14M
P/E Ratio
49.0x
PEG Ratio
-0.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
1.5x
Debt/Equity
2.0x
ROE
-509.9%
ROA
-256.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vicarious Surgical Inc. (RBOT) Business Model
About Vicarious Surgical Inc.
What They Do
Develops advanced robotic solutions for surgeries.
Business Model
The company designs and develops proprietary surgical robots that incorporate virtual reality technology, which enhances visualization and control for surgical teams during minimally invasive procedures. Its revenue model is likely derived from the sale and leasing of these robotic systems to hospitals and surgical centers, along with potential service agreements and training programs.
Additional Information
Vicarious Surgical is positioned as a leader in the medical technology space, focusing on improving patient outcomes and reducing recovery times. The integration of robotics and virtual reality in surgical practices signifies its role in transforming healthcare methodologies and enhancing the accessibility of complex surgeries.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
26
CEO
Mr. Stephen From
Country
United States
IPO Year
2017
Website
www.vicarioussurgical.comVicarious Surgical Inc. (RBOT) Latest News & Analysis
Latest News
Quick Summary
Vicarious Surgical Inc. (OTCQB: RBOT) reported its financial results for Q1 2026, ending March 31. Further details on performance were not provided in the excerpt.
Why It Matters
Vicarious Surgical's Q1 financial results may indicate growth potential or challenges, impacting stock performance and investor sentiment in the robotics and healthcare sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. (OTCQB: RBOT) completed initial benchtop testing for its surgical instruments aimed at ventral hernia repair, advancing towards design validation and clinical readiness.
Why It Matters
Successful testing of Vicarious Surgical's instruments boosts confidence in their upcoming product launch, potentially increasing market value and attracting investor interest in innovative healthcare technology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
1 month ago
Quick Summary
Vicarious Surgical Inc. has received approval to upgrade its Class A common stock to the OTCQB Venture Market, enhancing its market visibility.
Why It Matters
Vicarious Surgical's upgrade to the OTCQB may enhance visibility and credibility, potentially attracting more investors and improving liquidity for its shares.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. aims to improve its financial position and trading liquidity through strategic actions, supporting a potential relisting of its stock on a national exchange.
Why It Matters
Vicarious Surgical's strategic actions to improve financial stability and liquidity, along with potential relisting plans, can enhance investor confidence and drive stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. reported Q4 2025 operating expenses of $9.3 million, down 38% from $15.0 million in Q4 2024, indicating improved cost management.
Why It Matters
Decreased operating expenses indicate improved cost management, potentially enhancing profitability and investor confidence in Vicarious Surgical's future performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The NYSE has initiated delisting proceedings for Vicarious Surgical Inc. (RBOT) due to regulatory compliance issues, with immediate suspension of trading.
Why It Matters
The delisting of Vicarious Surgical Inc. signals potential financial distress, impacting investor confidence and liquidity for RBOT shares.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RBOT Stock
What is Vicarious Surgical Inc.'s (RBOT) stock forecast for 2026?
Analyst forecasts for Vicarious Surgical Inc. (RBOT) are not currently available. The stock is trading at $0.55.
Is RBOT stock a good investment in 2026?
According to current analyst ratings, RBOT has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RBOT stock?
Price predictions from Wall Street analysts for RBOT are not currently available. The stock is trading at $0.55.
What is Vicarious Surgical Inc.'s business model?
The company designs and develops proprietary surgical robots that incorporate virtual reality technology, which enhances visualization and control for surgical teams during minimally invasive procedures. Its revenue model is likely derived from the sale and leasing of these robotic systems to hospitals and surgical centers, along with potential service agreements and training programs.
What is the highest forecasted price for RBOT Vicarious Surgical Inc.?
Price targets from Wall Street analysts for RBOT are not currently available. The stock is trading at $0.55.
What is the lowest forecasted price for RBOT Vicarious Surgical Inc.?
Price targets from Wall Street analysts for RBOT are not currently available. The stock is trading at $0.55.
What is the overall RBOT consensus from analysts for Vicarious Surgical Inc.?
The overall analyst consensus for RBOT is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are RBOT stock price projections?
Stock price projections, including those for Vicarious Surgical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 12:51 PM UTC